Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeBioSelf TechnologyBioself Technology in the U.K. Accelerates with Sensate II Launch

Bioself Technology in the U.K. Accelerates with Sensate II Launch

BioSelf Technology aims to buck current start-up business trends with stress-busting consumer wearable, originally created for PTSD sufferers.

Following the sellout success of its Sensate device in 2018, UK technology startup BioSelf Technology announces the launch of its next-generation, Sensate II device, which goes on sale on 5 May 2020.

This stress-busting wearable device was created to deliver the health benefits of meditation, but without the need for years of practice. It also helps reduce stress-related ailments including sleep problems, heart conditions, obesity and other preventable health issues in just a 10-minute session, daily.

Designed to regulate the nervous system and tone the vagus nerve – the neural superhighway that connects the brain to the gut, Sensate II calms the “fight, flight, freeze” emergency response provoked by stress.

Stefan Chmelik, founder of BioSelf Technology and creator of Sensate, explains: “Stress and mental health issues are a 21st-century health crisis, with around 300 million people globally suffering from depression and anxiety.

10 minutes of deep relaxation is like a super-charged power nap as Sensate’s infrasound is designed to ‘massage’ the vagus nerve with precise vibrations that soothe and calm the user, from the first session”.

Developed and tested in a Harley Street clinic over the last three years, Sensate II has a 98% positive patient outcome. Perfect for home or office use, it works best in a quiet space and is compact enough to use anywhere when you just need to relax. While modern life may have changed the nature of stress, Sensate is a shortcut to ultimate relaxation.

Following the sellout prototype Sensate’s introduction in 2018, Sensate II’s upgrades include:

  • Improved ergonomic design builds on the already classic ‘pebble’ concept.

  • An entirely new way to transmit “felt sound” in the low-frequency register into the human body, with the totally redesigned engine.

  • Prototype Sensate achieved single-frequency sound, while Sensate II has been upgraded to create multi-layer frequency, boosting impact and nuance.

  • 800% increase in battery life

Users of 1,000 prototype Sensate devices report:

  • Feeling instantly relaxed

  • Improved deep sleep (tracked with a sleep tracker)

  • Lower resting heart rate and heart palpitations

  • Improved blood pressure readings

  • Better stress management

  • Reduced anxiety and depression levels

  • Feeling happier

  • A profound calming effect

  • Improved focus

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy